Navigation Links
HemoShear Co-Founder Presents Recommendations for Funding of Breakthrough Technologies to U.S. House of Representatives Committee on Science, Engineering and Technology
Date:7/26/2013

CHARLOTTESVILLE, Va., July 26, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced that Dr. Brian R. Wamhoff, co-founder of HemoShear, was invited to present his recommendations on improvements to the U. S. government's Small Business Technology Transfer program to stimulate translation of new discoveries from academia to the marketplace.  Dr. Wamhoff's testimony was given on Wednesday at a hearing of the U.S. House of Representatives Committee on Science, Engineering and Technology for the purpose of guiding the draft of new legislation entitled "Innovative Approaches to the Technology Transfer Act of 2013".  Dr. Wamhoff was the only industry representative selected to present to the Committee. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

Dr. Wamhoff is currently Vice President of Research and Development for HemoShear LLC, a biotechnology research company that is transforming the productivity and success rates of new drug R&D in the pharmaceutical industry.  He was formerly Associate Professor at the University of Virginia Department of Medicine, Cardiovascular Division, where he co-invented the HemoShear technology with Dr. Brett Blackman.  

"Having transitioned recently from academic researcher to entrepreneur, I benefitted from the creativity and resources that academic environments provide, while also encountering cultural challenges of translating a new technology from a university lab to a commercial enterprise.  My fellow academic researchers would benefit from appropriate incentives to translate their science, yet at the same time they need structure and accountability," said Dr. Wamhoff.

Drs. Wamhoff's and Blackman's paradigm-shifting technology, which became the foundation of HemoShear, is the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear's human-relevant systems are being rapidly adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Several institutes within the National Institutes of Health are funding programs with HemoShear, including the National Heart, Lung and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; and the National Cancer Institute.

In the past forty years, there has been little progress in development of systems that accurately predict human response to new drug candidates.  As a result, more than 90% of new drugs fail in clinical trials, often after companies have spent hundreds of millions of dollars in late stage clinical trials.  The pharmaceutical industry has been consolidating and is seeking answers to reduce costs and improve success rates for new drugs.  HemoShear has repeatedly demonstrated its ability to predict new drug successes and failures.  The Company aims to improve the industry's return on capital, save billions of dollars by avoiding misdirected research, and bring innovative treatments to patients at lower cost.

Dr. Wamhoff's testimony and further information on the Committee's activities regarding the Small Business Technology Transfer program may be found at the following locations:

http://science.house.gov/sites/republicans.science.house.gov/files/documents/HHRG-113-SY14-WState-BWamhoff-20130724.pdf

http://science.house.gov/press-release/subcommittee-looks-improve-transfer-technologies-lab-market  

http://science.house.gov/hearing/subcommittee-research-and-technology-improving-technology-transfer-universities-research

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Announces Advancement of Predictive Drug Safety Systems
2. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
3. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
4. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
5. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
6. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
7. SynCardia Co-Founder Honored with Pioneer in Transplantation Award at ISHLT
8. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
9. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
10. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
11. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... Milwaukee, WI (PRWEB) , ... March 29, 2017 , ... ... as its exclusive provider of co-op eligible dealer websites for its network of more ... line of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts ... in taking the natural next step to protect their new companion. Says Evan Dunbar, ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Youth Futures International ... success and feedback from high school and college students who have participated in the ... July 7-23 and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... insight into the challenges employers face in trying to balance both short-term and ... benefits programs? Adding to the growing complexity, companies are finding that the ...
Breaking Medicine News(10 mins):